Bayer AG - ADR
BAYRY
Get informed when a big investor buys or sells
+ FollowMarket Cap$54.82B
Close$
Earnings Call Q4 2025
March 4, 2026 - AI Summary
2025 Performance and Financials: Bayer reported sales of EUR 45.5 billion, core earnings per share of EUR 4.91, and free cash flow of EUR 2.1 billion. This performance met the company's improved guidance set earlier in the year despite litigation challenges impacting financial metrics.
2026 Outlook: For 2026, Bayer expects net sales between EUR 45 billion and EUR 47 billion, with core earnings per share projected to remain stable at approximately EUR 4.30 to EUR 4.80. However, the company anticipates a negative free cash flow forecast of minus EUR 1.5 billion to minus EUR 2.5 billion due to ongoing litigation-related payouts.
Litigation Concerns: Bayer continues to face significant litigation risks, particularly with glyphosate-related settlements that total around EUR 11.8 billion in provisions. The company anticipates substantial litigation payouts, which will pressure free cash flow and may affect capital allocation, including dividends.
Exclusive for Stockcircle Pro members
Sign up
$6.15
55.9% downside
Current Fair Value
55.9% downsideOvervalued by 55.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $54.82 Billion |
|---|---|
| Enterprise Value | $90.36 Billion |
| Dividend Yield | $0.03 (0.23%) |
| Earnings per Share | $-0.88 |
| Beta | 0.83 |
| Outstanding Shares | 3,929,696,328 |
Return
| Return on Equity | -6.14% |
|---|---|
| Return on Assets | -1.69% |
| Return on Invested Capital | 7.14% |
Valuation & Multiples
| P/E Ratio | -27.37 |
|---|---|
| PEG | 12.92 |
| Price to Sales | 1.16 |
| Price to Book Ratio | 1.99 |
| Enterprise Value to Revenue | 1.91 |
| Enterprise Value to EBIT | 16.88 |
| Enterprise Value to Net Income | -50 |
| Total Debt to Enterprise | 0.44 |
| Debt to Equity | 1.35 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.21
Average shareholder expectationRevenue Estimate
$12.55 B
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.13
Average shareholder expectationRevenue Estimate
$11.39 B
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.17%▼ 0.00% |
|---|---|
| Total Invested | $93.52M▲ 18.77% |
| Investors Holding | 15▼ 1.00% |
ESG Score
No data
About Bayer AG
CEO: Werner Baumann Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Ani...